Logo1 (06torrentlogo1)
Darifenacin Tablet, Extended Release
Product Images NDC 72162-2570
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Darifenacin (NDC 72162-2570). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Logo2 (07torrentlogo2)
Figure1 (Figure 1)
A line chart showing the mean plasma concentration (ng/mL) of Darifenacin over 24 hours post-dose for 7.5 mg and 15 mg extended-release oral tablets. The chart includes error bars representing standard deviation and compares concentration levels between the two doses across multiple time points.*
Figure 2a Study 1 (Figure2a Study1)
A line graph showing the median reduction in incontinence episodes per week from baseline over 12 weeks. It compares placebo, Darifenacin 7.5 mg, and Darifenacin 15 mg, with reductions plotted at weeks 2, 6, and 12. Both Darifenacin doses show greater reductions than placebo, with 15 mg having the largest effect.*
Figure 2b Study 2 (Figure2b Study2)
A line graph showing median reduction in incontinence episodes per week over 12 weeks for Darifenacin 7.5 mg, Darifenacin 15 mg, and placebo groups. The y-axis represents median reduction with 95 percent confidence intervals from baseline, while the x-axis shows time in weeks (0, 2, 6, 12). Data points indicate that both Darifenacin doses show greater reductions compared to placebo.*
Figure 2c Study 3 (Figure2c Study3)
A line graph showing median reduction in weekly incontinence episodes over 12 weeks for Darifenacin 15 mg compared to placebo. The x-axis represents time in weeks (0, 2, 6, 12), and the y-axis shows median reduction from baseline in incontinence episodes per week. Darifenacin 15 mg shows a greater reduction over time with error bars indicated, compared to placebo.*
Label (Lbl721622570)
Darifenacin Extended-Release Tablets 7.5 mg label features the NDC 72162-2570, with packaging for 30 tablets. The label states each film-coated extended-release tablet contains 8.930 mg Darifenacin Hydrobromide equivalent to 7.5 mg Darifenacin. It includes storage instructions, child-resistant container information, and manufacturer Bryant Ranch Prepack, Inc., with manufacturing by Torrent Pharmaceuticals Ltd.*
Structure (Structure)
Chemical structure of darifenacin, showing its molecular framework with characteristic rings and functional groups as depicted in the image.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
